# SynOmix Version Comparison: v6.0 → v7.0

## Summary

| Aspect | v6.0 | v7.0 |
|--------|------|------|
| Cancer Types | 3 | **7** (+4) |
| Drug Targets | 0 | **21** |
| Survival Analysis | ❌ | ✅ |
| Cell Deconvolution | ✅ | ✅ |

## New Features in v7.0

### 1. Survival Analysis
```
┌────────────────────────────────────┐
│ 📈 Prognostic Analysis             │
│                                    │
│ Risk Score: 65%                    │
│ Risk Group: Intermediate-High      │
│ 5-Year Survival: 50-70%            │
│                                    │
│ ⚠ High proliferation               │
│ ⚠ TP53 mutation                    │
│ ✓ High immune response             │
└────────────────────────────────────┘
```

### 2. Drug Recommendations
```
┌────────────────────────────────────┐
│ 💊 Actionable Drug Targets         │
│                                    │
│ ERBB2 - High expression   FDA ✓   │
│ • Trastuzumab                      │
│ • Pertuzumab                       │
│                                    │
│ PIK3CA - Mutated (15%)    FDA ✓   │
│ • Alpelisib                        │
└────────────────────────────────────┘
```

### 3. New Cancer Types

| Cancer | Subtypes Added |
|--------|---------------|
| Prostate | Luminal, Basal, Neuroendocrine |
| Ovarian | HG Serous, LG Serous, Clear Cell |
| Pancreatic | Classical, Basal-like, MSI-H |
| Melanoma | BRAF, NRAS, Triple WT |

### 4. Start Over Button
- One-click reset to upload new data
- No page refresh needed

## Clinical Workflow (v7.0)
```
Upload Data → Subtype Prediction → Microenvironment
     ↓              ↓                    ↓
  5 layers    Confidence %         Cell composition
                   ↓                    ↓
           Survival Analysis → Drug Recommendations
                   ↓                    ↓
             Risk group          FDA-approved Rx
```

---
*Generated: December 25, 2025*
